Skip to main content

Advertisement

SpringerLink
Log in

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Interleukin 10 (IL10) is a poor prognostic marker in several cancers. Its role in breast cancer is not well elucidated. The present study is designed to see the expression of IL10 in breast cancer tissue and to evaluate its correlation with the established markers of prognosis. Sixty female patients who underwent surgery for breast cancer were enrolled for the study. Immediately after surgery, 2–5 g of tumour tissue and similar volume of peritumoural normal breast tissue were collected for IL10 assay. IL10 expression was assayed by immunohistochemistry. IL10 expressing tumours and IL10 non expressing tumours were compared. Chi square/Fisher exact test and student’s t test were used to compare the data. p- valueless than 0.05 was considered as statistically significant. Thirty six patients (60 %) of carcinoma breast showed IL 10 expression in tumour tissue as compared to no IL 10 expression in any peritumouralnormal breast tissue (p < 0.01). IL10 expression had statistically significant correlation with locally advanced disease, tumour grade, HER2 + ve tumours and ER-ve, PR-ve, HER2 + ve breast cancer subtypes (p = 0.001, 0.001, 0.001 and 0.01 respectively). No correlation could be found with patient’s age, tumour size, tumour histology and ER and PR status. Correlation of IL10 expressing tumours with several established poor prognostic markers of breast cancer may indicate the possible association of IL10 expression with poor prognosis. Large studies with long term follow up are needed to substantiate the association of IL10 with poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52–62

    Article  PubMed  Google Scholar 

  2. Hicks D, Turner B (2015) Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward"precision" cancer therapy. Biotech Histochem. 90:81–92

    Article  CAS  PubMed  Google Scholar 

  3. Wang J, Ding Q, Shi Y, et al. (2012) The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis 27:305–312

    Article  CAS  PubMed  Google Scholar 

  4. Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14:e218–e228

    Article  CAS  PubMed  Google Scholar 

  5. Hamidullah, Changkija B, Konwar R (2012) Role of interleukin-10 in breast cancer. Breast Cancer Res Treat 133:11–21

    Article  CAS  PubMed  Google Scholar 

  6. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76

    Article  CAS  PubMed  Google Scholar 

  7. Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interf Cytokine Res 19:697–703

    Article  CAS  Google Scholar 

  8. Venetsanakos E, Beckman I, Bradley J, Skinner JM (1997) High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 75:1826–1830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Llanes-Fernández L, Alvarez-Goyanes RI, Arango-Prado Mdel C, et al. (2006) Relationship between IL-10 and tumor markers in breast cancer patients. Breast 15:482–489

    Article  PubMed  Google Scholar 

  10. Chavey C, Bibeau F, Gourgou-Bourgade S, et al. (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9:R15

    Article  PubMed  PubMed Central  Google Scholar 

  11. Heckel MC, Wolfson A, Slachta CA, et al. (2011) Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol 266:143–153

    Article  CAS  PubMed  Google Scholar 

  12. Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82–84

    PubMed  Google Scholar 

  13. Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57:51–58

    Article  PubMed  PubMed Central  Google Scholar 

  14. Eberl MM, Fox M, Edge CH, Carter SB, C, Mahoney, M. C (2006) BI-RADS classification for management of abnormal mammograms. J Am Board Fam Med 19:161–164

    Article  PubMed  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  16. Ghosh R, Sharma A, Mitra DK, Agarwal SK, Dinda AK, Saxena A (2013) Study of CC chemokine receptor 5 in renal allograft rejection. Indian J Nephrol 23:196–200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features andsurvival. Clin Med Res 7:4–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Son KS, Kang HS, Kim SJ, et al. (2010) Hypomethylation of the interleukin-10 gene in breast cancer tissues. Breast 19:484–488

    Article  PubMed  Google Scholar 

  19. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D (1999) Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Investig 28:29–41

    Article  CAS  Google Scholar 

  20. Halak BK, Maguire HC Jr, Lattime EC (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59:911–917

    CAS  PubMed  Google Scholar 

  21. Sabat R (2010) IL-10 family of cytokines. Cytokine Growth Factor Rev 21(5):315–324

    Article  CAS  PubMed  Google Scholar 

  22. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368

    Article  CAS  PubMed  Google Scholar 

  23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Sci 235:177–182

    Article  CAS  Google Scholar 

  24. Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. Breast 23:128–136

    Article  PubMed  Google Scholar 

  25. Su Y, Zheng Y, Zheng W, et al. (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: apopulation-based cohort study. BMC Cancer 11:292

    Article  PubMed  PubMed Central  Google Scholar 

  26. Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, et al. (2013) Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol 130:609–614

    Article  CAS  PubMed  Google Scholar 

  27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptorand Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217–1226

    Article  CAS  PubMed  Google Scholar 

  28. O’Brien KM, Cole SR, Tse CK, et al. (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer study. Clin Cancer Res 16:6100–6110

    Article  PubMed  PubMed Central  Google Scholar 

  29. WJl J, HX J, HY F, YP Y, Chen K, FX S (2014) HER2-enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy. Asian Pac J Cancer Prev 15:315–320

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India

    Hemanga Kumar Bhattacharjee, Virinder Kumar Bansal, Bikash Nepal & Mahesh C. Misra

  2. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

    Sandeep Srivastava & Amit K. Dinda

Authors
  1. Hemanga Kumar Bhattacharjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virinder Kumar Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bikash Nepal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sandeep Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amit K. Dinda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mahesh C. Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virinder Kumar Bansal.

Ethics declarations

Work has been approved by Institute’s Ethics Committee.

Conflict of Interest Statement

There is no conflict of interest.

Funding Source

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhattacharjee, H.K., Bansal, V.K., Nepal, B. et al. Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?. Indian J Surg Oncol 7, 320–325 (2016). https://doi.org/10.1007/s13193-016-0512-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0512-6

Keywords

Search

Navigation